A Review of Neurological Complications of COVID-19

Mack Sheraton 1, Neha Deo 2, Rahul Kashyap 3, Salim Surani 4, 5, 6

1. Emergency Medicine, Trinity West Medical Center, Mopfi Em Program, Steubenville, USA  2. Miscellaneous, Mayo Clinic Alix School of Medicine, Rochester, USA  3. Critical Care, Mayo Clinic and Foundation, Rochester, USA  4. Internal Medicine, Texas A&M Health Science Center, Bryan, USA  5. Internal Medicine, Corpus Christi Medical Center, Corpus Christi, USA  6. Internal Medicine, University of North Texas, Dallas, USA

Corresponding author: Salim Surani, srsuran@hotmail.com

Abstract
The SARS-CoV-2, a novel virus has shown an association with central nervous system (CNS) symptoms. Initial retrospective studies emerging from China and France, as well as case reports from different parts of the world revealed a spectrum of neurological symptoms ranging from a simple headache to more serious encephalitis and dysexecutive syndromes. Authors have tried to explain this neurotropism of the virus by comparing invasion mechanisms with prior epidemic coronavirus like severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Concrete evidence on those viruses has been limited. This review attempts to discuss various pathophysiological mechanisms as it relates to neurological complications of SARS-CoV-2. We will also discuss the neurological manifestations seen in various retrospective studies, systemic reviews, and case reports.

Introduction And Background
The COVID-19 pandemic has affected people worldwide and poses a severe health threat on a global scale. SARS-CoV-2 first emerged in December 2019, with a report of severe flu-like illness in Wuhan, Hubei Province, China. In January 2020, the causative pathogen was identified as a novel coronavirus, subsequently named SARS-CoV-2. In February 2020, the World Health Organization (WHO) coined the term "COVID-19" in reference to Coronavirus Disease 2019 [1]. As of 24 April 2020, over 2.8 million laboratory-confirmed cases have been reported in 184 countries. Unfortunately, COVID-19 has resulted in over 200,000 deaths out of which more than 55,000 have been in the United States [2]. In spite of such widespread morbidity and mortality there are paucity of studies examining neurological effects of the infection caused by SARS-CoV-2 [3]. For purposes of this review, we will describe neurological manifestations under three categories namely central nervous system (CNS) effects, peripheral nervous system (PNS) effects, and skeletal muscular injury due to SARS-CoV-2. All the cases whose locations have not been explicitly mentioned are from the United States.

Pathophysiology
Grossly, the pathophysiology of COVID-19 can be explained in terms of an invasion of cells in host body by SARS-CoV-2, resulting in inflammatory response and symptoms [4]. Steardo et al. [5] hypothesized that like all six of the other beta coronaviruses, SARS-CoV-2 are also neurotropic. The key to the entry of the virus is via the angiotensin converting enzyme 2 (ACE2) receptors expressed in both the neurons and glial cells of the brain. These receptors are predominantly present in the brain stem and in the regions responsible for regulation of cardiovascular function including subfornical organ, paraventricular nucleus, nucleus of the tractus solitarius, and rostral ventrolateral medulla. However, like both severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), the virus might also take a direct trans-synaptic route via the olfactory bulb upon inhalation without using the ACE2 receptors. After invasion, the virus causes reactive astrogliosis and activation of microglia setting off a massive neuroinflammatory cascade. Simultaneously, the systemic inflammation associated with SARS-CoV-2 infection compromises the blood brain barrier (BBB) which severely disturbs brain homeostasis and causes death of neuronal cells. Subsequently, infection of the brain stem may affect chemo sensory neural cells associated with respiratory and cardiovascular regulation as well as neurons of the respiratory center. Proper functioning of the autonomic nervous system requires that both afferent and efferent limbs are functioning which helps to restore and keep the hemostasis functioning at the optimal level. This damages the ventilatory lung function and exacerbates respiratory failure resulting in profound hypoxia. Combination of hypoxia with existent neuro-inflammation causes damage to the hippocampal and cortical areas resulting in the neuropsychiatric effects of the virus [5].

Wu et al. proposed a blood circulatory pathway, by which the virus directly infects the CNS, releasing inflammatory mediators and increasing the permeability of BBB [6]. They also reiterated the mechanism of
simultaneous immune and hypoxic injury to be responsible for the neuropathology. They hypothesized that once the virus gains entry into the CNS after crossing the BBB, clearance is difficult as the nervous system lacks the major histocompatibility antigens, and the immune response is restricted to cytotoxic T lymphocytes. Eventually, the patient develops either acute encephalitis, infectious toxic encephalopathy, or acute cerebrovascular attacks (CVAs). Acute encephalitis presents as an inflammatory lesion in the brain parenchyma causing spectrum of symptoms ranging from headaches to seizures. Infectious toxic encephalopathy is a reversible brain dysfunction syndrome caused by cerebral edema due to factors such as systemic toxemia, metabolic disorders, and hypoxia which could result in delirium and coma. Wu and colleagues also proposed that the virus-mediated cytokine storm and coagulation abnormalities as evidenced by abnormal d-dimer and platelets, increase the chance of acute CVA among patients infected with SARS-CoV-2 [6]. Kabbani and Olds proposed that the nicotine stimulation of the nACh receptor can increase ACE2 expression in neural cells, placing smokers at a higher risk for neurological complications by SARS-CoV-2 infection [7].

Review

Central nervous system effects

Most of our knowledge about CNS effects comes from the two retrospective observational case series from China and one ICU-based observational study from France. Mao et al. described neurological symptoms in COVID-19 patients hospitalized at three designated COVID hospitals in Wuhan, China between 16 January 2020 and 19 February 2020. Mao and co-workers reported that 36.4% of the 214 patients had neurological symptoms. Some 24.8% of these patients exhibited CNS symptoms, the most common of which were dizziness (16.8%) and headache (15.1%). Other CNS presentations included alteration of mental status (AMS), acute CVA, ataxia, and seizures. CNS complications, except for AMS and CVA were manifested early in course of the infection especially in patients who were severely infected. Both ischemic and hemorrhagic types of CVA were seen, with ischemic strokes being the common one. Specifically, the more severely affected patients with CNS symptoms showed lower lymphocyte counts, lower platelets count, and higher blood urea nitrogen in their laboratory studies than those without the CNS symptoms [8]. Li et al., conducted a single center retrospective analysis of COVID19 patients admitted to the Union Hospital in Wuhan, China between 16 January 2020 and 29 February 2020. Of the 221 patients studied, 11 had ischemic CVA, one had a central venous sinus thrombosis, and one had a hemorrhagic stroke. Similarly, CVA symptoms usually appeared later in course of the disease and in more severely affected patients. The affected patients were older and had risk factors as prior CVA, and co-morbidities as diabetes, hypertension, and cardiovascular diseases. Laboratory studies revealed increased inflammatory markers [white blood cell (WBC), neutrophils, C-reactive protein (CRP), and d-dimer] and evidence of multi-organ involvement in the form of elevated liver enzymes and abnormal renal function tests. Early institution of anticoagulation therapy among these ischemic CVA patients showed benefit [9].

Helms et al. reported neurological complications in an observational case series of 58 patients admitted to the ICU for ARDS, secondary to COVID-19 in Strasbourg, France, between 5 March 2020 and 3 April 2020. Neurological findings were seen in 14% of patients at admission and 69% of cases were seen when they were weaned off sedation and paralysis. Most frequently observed symptoms were agitation (69%), upper motor neuron syndrome signs like hyperreflexia with clonus and positive Babinski’s sign (69%) during the ICU stay, and a dysexecutive syndrome (33%) after discharge. MRI of the brain in patients who underwent electroencephalogram (EEG) showed findings consistent with encephalopathy [10]. Chen et al. reported COVID-19 symptoms in 99 hospitalized cases between 1 January and 20 January 2020, in a retrospective single center study at Wuhan, China. The CNS symptoms of headache were present among 8% and AMS were seen among 9% of cases [11]. Huang et al. in a prospective study of 41 patients reported headache in 8% of the cases [12]. Similarly, Yang et al. in a retrospective analysis of 52 critically ill patients found headache in 6% of cases [13]. Yet another retrospective case series of 138 hospitalized patients conducted by Wang et al. reported dizziness in 9% and headache in 7% of the cases [14]. All of these studies were patients from Wuhan, China. A retrospective study done in Zhejiang province, China had 66 patients hospitalized between 10 January 2020 and 26 January 2020 found the incidence of headache to be much higher at 34% [15]. Overall, the headache is very nonspecific symptoms among any viral or bacterial illness, but they were seen consistently higher among patients who were infected with SARS-CoV-2 virus.

Filatov et al. reported the case of a 74-year-old man who was COVID-19 positive and presented with encephalopathy. The CT scan of head and cerebrospinal fluid (CSF) studies were negative for any infection. EEG showed evidence of encephalopathy, focal temporal lobe dysfunction, and possible ictal epileptogenicity [16]. Karimi et al. reported a 30-year-old woman in Sari, Iran who presented with the new onset tonic-clonic seizures and was found positive for SARS-CoV-2. Brain MRI and CSF studies were negative, as were CSF cultures and CSF PCR for the corona virus [17]. Moriuchi et al. reported the case of a 24-year-old male in Yamanashi, Japan who presented with symptoms of loss of consciousness (LOC), AMS, neck stiffness, and subsequently status epilepticus for which he required intubation. Surprisingly, nasopharyngeal swabs in this case tested negative on SARS-CoV-2 PCR, but the spinal fluid was positive for SARS-CoV-2. Other laboratory studies revealed leukocytosis, lymphopenia, and elevated CRP. MRI of the brain showed right lateral ventriculitis and encephalitis mainly on right mesial lobe and hippocampus which
was presumed to be due to hippocampal sclerosis accompanying postconvulsive encephalopathy [18]. Anticonvulsants were used in the treatment for seizures with encouraging results. Lu et al. conducted a retrospective multi-center study involving 304 COVID-19 positive patients admitted to 42 government hospitals in China, during the period between 18 January 2020 and 18 February 2020, which failed to reveal any new-onset seizure in this cohort. They did have two subjects who demonstrated seizure like activity, but these were subsequently confirmed to have acute stress reaction and hypocalcemia rather than seizure [19].

Poyiadji et al. reported the case of a female in her late 50s who presented with AMS, besides other symptoms. She was diagnosed with COVID-19. Noncontrast CT scan of head showed symmetric hypo-attenuation within the bilateral medial thalami and MRI demonstrated hemorrhagic rim enhancing lesions within the bilateral thalami, medial temporal lobes, and sub insular regions. Based on these findings the patient was diagnosed with acute hemorrhagic necrotizing encephalopathy (AHNE) and was treated with intravenous immunoglobulins (IV IgG) [20]. Sharifi-Razavi et al. reported the case of a 79-year-old COVID-19 positive man, from Sari, Iran who presented with loss of consciousness. CT scan of the brain revealed a massive intracerebral hemorrhage (ICH) in the right hemisphere, accompanied by intraventricular and subarachnoid hemorrhage. Fluctuation in the blood pressure related to the virus’ interaction with ACE2 receptors was felt to be responsible for the ICH [21].

Peripheral nervous system effects

Mao et al. reported PNS effects in their study presenting in the form of dysgeusia (5.6%), dysosmia (5.1%), visual disturbances (1.4%), and neuralgia (2.3%). Unlike CNS abnormalities which were accompanied by changes in laboratory studies, there were no significant differences in the laboratory and CSF findings among patients with or without PNS symptoms [8]. Other studies report anosmia and ageusia as the predominantly presenting PNS symptoms. Bagheri et al. attempted to find a correlation between increased incidence of anosmia. They found significant correlation between anosmia and COVID-19 positivity in different provinces of Iran (Spearman correlation coefficient: 0.87, p-Value <0.001). Furthermore, those with anosmia were more likely to have dysgeusia and without typical fever/cough/dyspnea symptoms [22]. Giacomelli et al. surveyed 59 hospitalized patients on 19 March 2020 in Milan, Italy to study the olfactory and taste disturbances. They found that 10.2% have only taste symptoms, 5.1% have only olfactory symptoms while the rest 18.6% had both. They also found that subjects with these symptoms tended to be younger and female gender [23]. Lechein et al. studied 417 patients from 12 European hospitals, with mild to moderate forms of COVID-19. Some 85.6% reported olfactory dysfunction, of those 20.4% had anosmia, 12.6% phantosmia and 32.4% parosmia, with the remaining having hyposmia. Some 88.8% cases had gustatory disorders. Of those 78.9% had ageusia and rest of them had dysgeusia. These symptoms had high degree of correlation with each other and with female gender. Recovery was generally delayed over weeks with early recovery reported only in 44% of cases [24].

Gutiérrez-Ortiz et al. described two COVID-19 cases presenting with variants of Guillain–Barré syndrome (GBS) in Madrid, Spain. Their first patient was a 50-year-old man who presented with a two-day history of vertical diplopia, perioral paresthesia, and gait instability and was found to be COVID-19 positive from nasopharyngeal PCR. Examination revealed absent deep tendon reflexes (DTR) in the upper and in the lower limbs, right internuclear ophthalmoplegia, and right fascicular oculomotor palsy consistent with Miller–Fisher syndrome. Brain imaging with MRI and CSF laboratory studies as well as CSF culture failed to show any abnormality. The patient was treated with immunoglobulins (IV IgG) and had resolution of all of the symptoms except for anosmia and ageusia at the time of discharge. Their second patient was a 39-year-old man who presented with acute onset of diplopia and had a positive nasopharyngeal SARS-CoV-19 PCR. Physical examination showed loss of DTR and bilateral abducens palsy, consistent with polyneuritis cranialis. Other blood, CSF studies, and imaging were negative except for leucopenia. The patient received supportive outpatient treatment and had complete recovery [25]. Zhao et al. reported the case of a 61-year-old woman with a Wuhan travel history, who presented at Shanghai, China with acute lower extremity weakness and severe fatigue. Physical examination revealed areflexia and symmetric ascending lower motor neuron paralysis consistent with GBS. Initial laboratory studies showed thombocytopenia, lymphopenia and nerve conduction studies showed findings consistent with demyelinating neuropathy. Subsequent nasopharyngeal PCR was positive for COVID-19. She was admitted and treated with IV immunoglobulins (IV IgG) and had complete symptom resolution at 50 days [26]. Zhao et al. also reported a case of acute myelitis in a COVID-19 positive, 66-year-old man from Wuhan, China. The patient presented on the sixth day with acute flaccid myelitis of the lower limbs, urinary and bowel incontinence, and sensory level abnormality at T10 level. CT scan of brain revealed bilateral basal ganglia and paraventricular lacunar infarcts along with brain atrophy. The patient underwent treatment with a multitude of intravenous antibiotics, steroids, immunoglobulins (IV IgG) and Vitamin B12 and had significant improvement of his symptoms [27].

Skeletal muscle injury

Guan and co-workers in their retrospective study showed preliminary evidence of skeletal muscle injury associated with COVID-19 infection among 1099 patients from 550 hospitals in mainland China through January 2020. They found the prevalence of myalgias to be 14.9% amongst patients, with the rate increasing with the severity of illness. They also reported higher creatinine kinase (CK) levels greater than 200 U/L.
among 12.5% of nonsevere and 19% of severe cases. Only 0.2% were caused due to rhabdomyolysis [28]. Mao et al. also reported skeletal muscle injury in 10.7% cases out of which a significantly higher number were seen in patient with liver and kidney dysfunction [8]. Figure 1 shows the summary of major neurological abnormalities in COVID-19.

Till now there is not a whole lot of studies trying to elucidate neurological complications of SARS-CoV-2 evidently because such complications are not as common with this infection (Table 1).

FIGURE 1: Summary of major neurological abnormalities in COVID-19.
### Table 1: Summary of literature of neurological manifestations in COVID-19.

| Author                  | Study design          | Sample size | Findings                                                                                                                                                                                                 |
|-------------------------|-----------------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Aceti et al.            | Case report           | 2012 patients | Clinical manifestations included headache, fever, anosmia, and ageusia. 12% of patients had myalgia, 11.3% had fever, and 8.4% had anosmia. All patients had at least one symptom. |
| Bagheri et al.          | Case report           | 100 patients | The study reported neurological symptoms of headache, seizures, and encephalopathy. 37% of patients had fever, 27% had anosmia, and 13% had ageusia.             |
| Guadalupe-Cristo et al. | Case report           | 2019 patients | The study reported neurological symptoms of headache, seizures, and encephalopathy. 37% of patients had fever, 27% had anosmia, and 13% had ageusia.             |
| Lechien et al.          | Case report           | 301 patients | The study reported neurological symptoms of headache, seizures, and encephalopathy. 37% of patients had fever, 27% had anosmia, and 13% had ageusia.             |
| Lü et al.               | Case report           | 217 patients | The study reported neurological symptoms of headache, seizures, and encephalopathy. 37% of patients had fever, 27% had anosmia, and 13% had ageusia.             |
| Luo et al.              | Case report           | 302 patients | The study reported neurological symptoms of headache, seizures, and encephalopathy. 37% of patients had fever, 27% had anosmia, and 13% had ageusia.             |
| Mao et al.              | Case series           | 214 patients | The study reported neurological symptoms of headache, seizures, and encephalopathy. 37% of patients had fever, 27% had anosmia, and 13% had ageusia.             |
| Mitibachi et al.        | Case report           | 240 patients | The study reported neurological symptoms of headache, seizures, and encephalopathy. 37% of patients had fever, 27% had anosmia, and 13% had ageusia.             |
| Psyllaki et al.         | Case report           | 5 patients  | The study reported neurological symptoms of headache, seizures, and encephalopathy. 37% of patients had fever, 27% had anosmia, and 13% had ageusia.             |
| Shariat Razani et al.   | Case report           | 790 patients | The study reported neurological symptoms of headache, seizures, and encephalopathy. 37% of patients had fever, 27% had anosmia, and 13% had ageusia.             |
| Zhao et al.             | Case report           | 36 patients | The study reported neurological symptoms of headache, seizures, and encephalopathy. 37% of patients had fever, 27% had anosmia, and 13% had ageusia.             |
| Guan et al.             | Retrospective study   | 1009 patients | The study reported neurological symptoms of headache, seizures, and encephalopathy. 37% of patients had fever, 27% had anosmia, and 13% had ageusia.             |
Conclusions
The COVID-19 is just in its inception, but there is significant signal of neurological involvement. Our review suggests that neurological involvement in COVID-19 can have detrimental effect in the overall quality of life. Our review of pathophysiology hypothesized by various authors seems to indicate that CNS manifestations predominantly arises due to inflammatory causes, PNS due to immune-mediated mechanisms, and skeletal muscle injury due to the direct effects of the virus. However, study at the molecular levels are needed to accept or refute such theories with conviction. This would help in classifying the whole spectrum of neuropathology better, which in turn would help in developing consensus regarding better treatment modalities.

Additional Information
Disclosures
Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References
1. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March. (2020). Accessed: April 21, 2020: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march
2. COVID-19 Map. Johns Hopkins Coronavirus Resource Center. (2020). Accessed: April 21, 2020: https://coronavirus.jhu.edu/map.html.
3. Asadi-Pooya AA, Simani L: Central nervous system manifestations of COVID-19: a systematic review. J Neurol Sci. 2020, 415:116832. 10.1016/j.jns.2020.116832
4. Baig AM, Khaleeq A, Ali U, Syeda H: Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci. 2020, 11:995-998. 10.1021/acschemneuro.0c00122
5. Steardo L, Steardo L, Zorec R, Verkhratsky A: Neuroinfection may contribute to pathophysiology and clinical manifestations of COVID-19. Acta Physiol (Oxf). 2020, e13473. 10.1111/apha.13473
6. Wu Y, Xu X, Chen Z, et al.: Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun. 2020. 10.1016/j.bbi.2020.116832
7. Kabhani N, Olds L: Does COVID19 infect the brain? If so, smokers might be at a higher risk. Mol Pharmacol. 2020, 97:551-553. 10.1124/molpharm.120.000014
8. Mao L, Wang M, Chen S, et al.: Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: a retrospective case series study. medRxiv. 2020, 2020.10.20.20020650
9. Li Y, Wang M, Zhou Y, et al.: Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. Soc Sci Res Netw Electr J. 2020
10. Helms J, Kremer S, Merdjli H, et al.: Neurologic features in severe SARS-CoV-2 infection. N Engl J Med. 2020, 382:2082-2089. 10.1056/NEJMoa2008597
11. Chen N, Zhou M, Dong X, et al.: Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020, 395:507-513. 10.1016/S0140-6736(20)30211-7
12. Huang C, Wang Y, Li X, et al.: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020, 395:497-506. 10.1016/S0140-6736(20)30183-5
13. Yang X, Yu Y, Xu J, et al.: Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Resp Med. 2020, 10.1016/S2213-2600(20)30079-5
14. Wang D, Hu B, Hu C, et al.: Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020, 323:1061-1069. 10.1001/jama.2020.1585
15. Xu X-W, Wu X-X, Jiang X-G, et al.: Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-CoV-2) outside of Wuhan, China: retrospective case series. BMJ. 2020, 368:l1136. 10.1136/bmj.m606
16. Filatov A, Sharma P, Hindi F, et al.: Neurological complications of coronavirus disease (COVID-19): encephalopathy. Cureus J Med Sci. 2020, 12:10.7759/cureus.7352
17. Karimi N, Sharifi Razavi A, Rouhani N: Frequent convulsive seizures in an adult patient with COVID-19: a case report. Iran Red Crescent Med J. 2020, 20:5812. 10.5812/ircmj.102828
18. Moriyachi T, Harii N, Goto J, et al.: A first case of meningitis/encephalitis associated with SARS-CoV-2. J Infect Dis 2020, 201187.
19. Lu L, Xiong W, Liu D, et al.: New-onset acute symptomatic seizure and risk factors in coronavirus disease 2019: a retrospective multicenter study. Epilepsia. 2020. 10.1111/epi.17537
20. Poyiadji N, Shinohara A, Stone M, Patel S, Griffith B: COVID-19-associated acute hemorrhagic necrotizing encephalopathy: CT and MRI features. Radiology. 2020, 2011187. 10.1148/radiol.20202011187
21. Sharifi-Razavi A, Karimi N, Rouhani N: COVID-19 and intracerebral haemorrhage: causative or coincidental?. New Microbes New Infect. 2020, 35:100669. 10.1016/j.mmn.2020.100669
22. Bagheri SHR, Asghari AM, Farhadi M, et al.: Coincidence of COVID-19 epidemic and olfactory dysfunction outbreak. medRxiv. 2020, 10.1101/2020.03.25.20041889
23. Giacomelli A, Pezzati L, Conti F, et al.: Self-reported olfactory and taste disorders in patients with severe acute respiratory coronavirus 2 infection: a cross-sectional study. Clin Infect Dis. 2020, 10.1093/cid/ciaa330

24. Lechien JR, Chiesa-Estomba CM, De Siti DR, et al.: Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol. 2020, 1-11. 10.1007/s00405-020-05965-1

25. Gutiérrez-Ortiz C, Méndez A, Rodrigo-Rey S, et al.: Miller Fisher Syndrome and polyneuritis cranialis in COVID-19. Neurology. 2020, 10.1212/WNL.0000000000009619

26. Zhao H, Shen D, Zhou H, Liu J, Chen S: Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence?. Lancet Neurol. 2020, 10.1016/S1474-4422(20)30109-5

27. Zhao K, Huang J, Dai D, Peng Y, Liu L, Nie S: Acute myelitis after SARS-CoV-2 infection: a case report. medRxiv. 2020, 10.1101/2020.03.16.20035107

28. Guan W, Ni Z, Hu Y, et al.: Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020, 10.1056/NEJMoa2002032